Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon.
Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon.
复制标题
阿糖腺苷和人白细胞干扰素联合治疗骨髓移植后巨细胞病毒肺炎。
DOI：
10.1093/infdis/146.1.80
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
Thomas,ED
中科院分区：
文献类型：
--
作者：
Meyers,JD;McGuffin,RW;Bryson,YJ;Cantell,K;Thomas,ED
7例骨髓移植受者接受人白细胞干扰素和阿糖腺苷治疗巨细胞病毒肺炎。尽管5例患者活检和尸检肺标本中的平均病毒滴度从5 × 104降至1 × 10250%组织培养感染剂量，但几乎没有临床疗效证据，只有1例患者存活。4例患者因中性粒细胞计数下降而停止治疗，其中2例患者还显示重度神经毒性。这些药物的联合应用对骨髓移植后巨细胞病毒肺炎的治疗既不安全也不有效。
Seven marrow transplant recipients were treated with human leukocyte interferon and vidarabine for cytomegalovirus pneumonia. Although the mean virus titer in biopsy and autopsy lung specimens from five patients decreased from 5 × 104to 1 × 10250% tissue culture infective doses, there was little clinical evidence of efficacy and only one patient survived. Treatment was stopped in four patients because of declining neutrophil counts, and two of these four patients also showed severe neurotoxicity. The combination of these agents was neither safe nor effective for the treatment of cytomegalovirus pneumonia after marrow transplantation.